drugset / Trial / NCT03453840

Summary

This project determines the pharmacokinetic/pharmacodynamic (PK/PD) of an extended artemether-lumefantrine (AL) dosing regimen in HIV-infected children on efavirenz (EFV)-based antiretroviral therapy (ART) that is designed to improve the PK exposure and treatment efficacy of this artemisinins-based combination therapy (ACT) regimen. Our overarching goal is to inform the best treatment guidelines for young children in Africa. HIV-infected and HIV-uninfected children were enrolled for intensive PK studies, as well as additional children for population PK studies to enhance association analyses with clinical outcomes.

Timeline

Start
2018-02-21
Primary completion
2021-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether Small molecule 20 mg
Subject Artemether Small molecule 40 mg
Subject Artemether Small molecule 60 mg
Subject Artemether Small molecule 80 mg
Subject lumefantrine Small molecule 120 mg
Subject lumefantrine Small molecule 240 mg
Subject lumefantrine Small molecule 360 mg
Subject lumefantrine Small molecule 480 mg